Dashboard
1
With a growth in Net Sales of 19.67%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 221.6 MM
- NET SALES(HY) At CNY 319.89 MM has Grown at 30.09%
- ROCE(HY) Highest at 22.47%
2
With ROE of 20.12%, it has a very attractive valuation with a 5.12 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,887 Million (Small Cap)
25.00
NA
1.46%
-0.47
20.90%
2.19
Revenue and Profits:
Net Sales:
128 Million
(Quarterly Results - Mar 2026)
Net Profit:
34 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.65%
0%
-13.65%
6 Months
-18.67%
0%
-18.67%
1 Year
7.1%
0%
7.1%
2 Years
74.62%
0%
74.62%
3 Years
23.07%
0%
23.07%
4 Years
95.71%
0%
95.71%
5 Years
90.97%
0%
90.97%
Hunan Sundy Science & Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.04%
EBIT Growth (5y)
33.47%
EBIT to Interest (avg)
72.62
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.66
Tax Ratio
9.49%
Dividend Payout Ratio
42.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
19.57%
ROE (avg)
13.48%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
5.12
EV to EBIT
25.34
EV to EBITDA
23.28
EV to Capital Employed
7.42
EV to Sales
6.10
PEG Ratio
0.15
Dividend Yield
0.67%
ROCE (Latest)
29.30%
ROE (Latest)
20.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
127.70
106.70
19.68%
Operating Profit (PBDIT) excl Other Income
28.60
26.80
6.72%
Interest
0.00
0.00
Exceptional Items
-0.70
-0.30
-133.33%
Consolidate Net Profit
33.50
28.50
17.54%
Operating Profit Margin (Excl OI)
223.80%
210.10%
1.37%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 19.68% vs 18.95% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 17.54% vs 50.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
652.80
571.80
14.17%
Operating Profit (PBDIT) excl Other Income
208.70
166.20
25.57%
Interest
0.20
0.20
Exceptional Items
4.60
0.40
1,050.00%
Consolidate Net Profit
184.50
144.20
27.95%
Operating Profit Margin (Excl OI)
290.90%
259.60%
3.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.17% vs 24.30% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 27.95% vs 163.14% in Dec 2024
About Hunan Sundy Science & Technology Co., Ltd. 
Hunan Sundy Science & Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






